Program Book - Confex

ACR Poster Session A
Baeuerle 2 , Matthias Witt 2 , Axel P. Nigg 1 , Christiane Reindl 1 ,
Claudia Dechant 1 , Alla Skapenko 1 and Hendrik Schulze-
Koops 1 , 1 Division of Rheumatology and Clinical Immunology,
Med. Poliklinik, University of Munich, Munich, Germany,
2
Medizinische Poliklinik, Munich, Germany
388. Serum Cytokine Levels Predict Mortality Among
Postmenopausal Women Reporting Rheumatoid Arthritis.
Jeremy Sokolove 1 , William H. Robinson 2 , Brian T. Walitt 3 ,
Kevin D. Deane 4 , Yuefang Chang 5 , Russell Tracy 6 , V. Michael
Holers 7 , Lewis Kuller 5 , Larry W. Moreland 5 and Rachel
Mackey 5 , 1 Stanford University, Palo Alto, CA, 2 Stanford
University, Stanford, CA, 3 Washington Hospital Center,
Washington, DC, 4 University of Colorado School of Medicine,
Aurora, CO, 5 University of Pittsburgh, Pittsburgh, PA,
6
University of Vermont, Colchester, VT, 7 Univ of Colorado
School of Med, Aurora, CO
389. Treatment-Related Changes in Weight and Adipokine
Levels and Associations with Radiographic Progression
in Rheumatoid Arthritis. Joshua Baker 1 , Gary Toedter 2 ,
Daniel G. Baker 3 and Joan Marie Von Feldt 4 , 1 University
of Pennsylvania, Philadelphia, PA, 2 Centocor R&D, a
division of Johnson & Johnson Pharmaceutical Research
& Development, L.L.C., Malvern, PA, 3 Centocor R & D, a
division of Johnson & Johnson Pharmaceutical Research
and Development, LLC, Malvern, PA, 4 Univ of Pennsylvania/
Philadelphia VAMC, Philadelphia, PA
390. B Cell Activating Factor (BAFF) Binding Receptors (BBR)
on B Cells: Characterization in Patients with Rheumatoid
Arthritis (RA) Receiving Anti-TNF-a Agent Infliximab (IFX).
Lara Valor 1 , Diana Hernandez 2 , Geraldine Cambridge 3 ,
Maria J. Leandro 3 , Lina Martinez-Estupiñan 1 , Luis Carreño 1
and Inmaculada de la Torre 1 , 1 Gregorio Marañón Hospital,
Madrid, Spain, 2 Gregorio Maranon Hospital, Madrid, Spain,
3
University College of London, London, United Kingdom
391. Tumor Necrosis Factor Blocking Therapy Alters Oxidative
Stress and Hypoxia-Induced Mitochondrial Mutagenesis in
Inflammatory Arthritis. Monika Biniecka 1 , Aisling Kennedy 1 ,
Chin Teck Ng 1 , Ting C. Chang 1 , Emese Balogh 1 , Edward Fox 2 ,
Douglas J. Veale 1 , Ursula Fearon 1 and Jacintha N. O’Sullivan 3 ,
1
Translation Rheumatology Research Group, Dublin, Ireland,
2
Department of Pathology, University of Washington,
Seattle, WA, 3 Department of Surgery, Trinity Centre for
Health Sciences, St James’s Hospital, Dublin, Ireland
Rheumatoid Arthritis Treatment - Small Molecules, Biologics,
Therapy I
392. Active Smoking Is Not Associated with Treatment Response
In Early Rheumatoid Arthritis In a Large Randomized
Blinded Trial. Leann Maska 1 , James R. O’Dell 2 , Jeffrey R.
Curtis 3 , S. Louis Bridges Jr. 4 , Larry W. Moreland 5 , Stacey
Cofield 6 and Ted R. Mikuls 7 , 1 University of Nebraska Medical
Center, Omaha, NE, 2 Univ of Nebraska Med Ctr, Omaha, NE,
3
Univ of Alabama-Birmingham, Birmingham, AL, 4 Marguerite
Jones Harbert-Gene V. Ball, MD Professor of Medicine, and
Director, Division of Clinical Immunology and Rheumatology,
University of Alabama at Birmingham, Birmingham, AL,
5
University of Pittsburgh, Pittsburgh, PA, 6 Univ of Alabama at
Birmingham,, Birmingham, AL, 7 Omaha VA and University of
Nebraska, Omaha, NE
393. Effect of Disease Modifying Anti-Rheumatic Drugs
(DMARDs) On Anti-CCP2 and Anti-Citrullinated Protein
Antibody (ACPA) Levels During Longitudinal Assessments
In Rheumatoid Arthritis Patients. Makoto Soejima 1 , Aarat
M. Patel 1 , Danielle Goudeau 1 , Donald M. Jones 1 , Christine
L. Amity 1 , Lynne M. Frydrych 1 , Dawn McBride 1 , Derek
Sippel 1 , Heather Eng 2 , David Kyle 2 , Melissa Saul 2 , Stephen
R. Wisniewski 2 , Larry W. Moreland 1 and Marc C. Levesque 1 ,
1
Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2 Univ of
Pittsburgh, Pittsburgh, PA
394. Adalimumab Added to Methotrexate and Intra-Articular
Glucocorticoid Increases Remission Rates At One Year In
Early, DMARD-Naïve Patients with Rheumatoid Arthritis
- An Investigator-Initiated Randomized, Controlled,
Double-Blinded Study. Kim Hørslev-Petersen 1 , Merete L.
Hetland 2 , Peter Junker 3 , Jan Pødenphant 4 , Torkell Ellingsen 5 ,
Palle Ahlqvist 6 , Hanne M. Lindegaard 3 , Asta Linauskas 7 ,
Annette Schlemmer 8 , Mette Y. Dam 9 , Ib Hansen 10 , Hans
Chr Horn 6 , Anette Jørgensen 9 , Sophie B. Krintel 2 , Johnny
Raun 1 , Christian G. Ammitzbøll 9 , Julia Johansen 2 , Mikkel
Østergaard 11 and Kristian Stengaard-Pedersen 9 , 1 University
of Southern Denmark, Graasten, Denmark, 2 Copenhagen
University Hospital at Glostrup, Glostrup, Denmark, 3 Odense
University Hospital, Odense C, Denmark, 4 Copenhagen
University at Gentofte,, Hellerup, Denmark, 5 University
Hospital, Silkeborg, Denmark, 6 Vejle Hospital,, Vejle,
Denmark, 7 Vendsyssel Hospital, Hjørring, Denmark, 8 Aalborg
Hospital, Aalborg, Denmark, 9 Arhus University Hospital,
Aarhus, Denmark, 10 Viborg Hospital, Viborg, Denmark,
11
Copenhagen University Hospital at Glostrup, Copenhagen,
Denmark
395. Tocilizumab Improves Arterial Stiffness Compared with
Abatacept In Patients with TNF Blockers-Resistant
Active Rheumatoid Arthritis.An Open Label Randomized
Controlled Trial. Kensuke Kume 1 , Kanzo Amano 1 , Susumu
Yamada 1 and Kazuhiko Hatta 2 , 1 Hiroshima Clinic, Hiroshima,
Japan, 2 Hatta Clinic, Kure, Japan
396. Tocilizumab Monotherapy Improves BONE Mineral
Density AS Well AS TNF Blockers PLUS Methotrexate with
Methotrexate-RESISTANT Activerheumatoid Arthritis. AN
OPEN-Label RANDOMIZED CLINICAL TRIAL. T-BONE TRIAL.
Kensuke Kume 1 , Kanzo Amano 1 , Susumu Yamada 1 and
Kazuhiko Hatta 2 , 1 Hiroshima Clinic, Hiroshima, Japan, 2 Hatta
Clinic, Kure, Japan
397. Efficacy, Safety and Pharmacokinetics of Vidofludimus,
a Novel Oral Immunomodulator, in Patients with Active
Rheumatoid Arthritis on Methotrexate Background
Therapy: The COMPONENT Study. Stanislaw Sierakowski 1 ,
Bruno Dietrich 2 , Bernd Hentsch 2 and Aldo Ammendola 2 ,
1
Medical University Bialystok, Bialystok, Poland, 24 SC AG,
Planegg-Martinsried, Germany
2011 Program Book 163